Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada von Chu, Quincy, Sripada, Kaushik, Vaselenak, Sarah, Jovanoski, Nick, Arnold, Melina

Volltext

Severity of COVID-19 and adverse long-term outcomes: a retrospective cohort study based on a US electronic health record database von Jovanoski, Nick, Chen, Xin, Becker, Ursula, Zalocusky, Kelly, Chawla, Devika, Tsai, Larry, Borm, Michelle, Neighbors, Margaret, Yau, Vincent

Volltext

Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting von Jovanoski, Nick, Kuznik, Andreas, Becker, Ursula, Hussein, Mohamed, Briggs, Andrew

Volltext

Estimating the impact of adjuvant atezolizumab in preventing recurrences and reducing costs in resectable early PD-L1 high non-small cell lung cancer in Europe von Arnold, Melina, Jovanoski, Nick, Tomar, Akanksha, Dubey, Akansha, Yim, Yeun Mi, Napalkov, Pavel

Volltext

Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective von Yip, Chui-ying, Greystoke, Alastair, Abogunrin, Seye, Belleli, Rossella, Di Maio, Danilo, Rouse, Peter, Jovanoski, Nick

Volltext

Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence von Bowes, Kathleen, Jovanoski, Nick, Brown, Audrey E., Di Maio, Danilo, Belleli, Rossella, Chadda, Shkun, Abogunrin, Seye

Volltext

Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC) von Jovanoski, Nick, Abogunrin, Seye, Di Maio, Danilo, Belleli, Rossella, Hudson, Pollyanna, Bhadti, Sneha, Jones, Libby G.

Volltext

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer von Das, Millie, Ogale, Sarika, Jovanoski, Nick, Johnson, Ann, Nguyen, Caroline, Bhagwakar, Jan, Lee, Janet S

Volltext

Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence von Jovanoski, Nick, Bowes, Kathleen, Brown, Audrey, Belleli, Rossella, Di Maio, Danilo, Chadda, Shkun, Abogunrin, Seye

Volltext

Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review von Jovanoski, Nick, Abogunrin, Seye, Di Maio, Danilo, Belleli, Rossela, Hudson, Pollyanna, Bhadti, Sneha, Jones, Libby G.

Volltext

Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe von Greystoke, Alastair, Jovanoski, Nick, Napalkov, Pavel, Arnold, Melina

Volltext bestellen

Supplementary tables 1-4: Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.docx von Jovanoski, Nick, Bowes, Kathleen, Brown, Audrey, Belleli, Rossella, Di Maio, Danilo, Chadda, Shkun, Abogunrin, Seye

Volltext bestellen

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer. Supplementary material von S Lee, Janet, Bhagwakar, Jan, Nguyen, Caroline, Johnson, Ann, Jovanoski, Nick, Ogale, Sarika, Das, Millie

Volltext bestellen